Mikhail Byakhow

1.5k total citations · 1 hit paper
2 papers, 1.0k citations indexed

About

Mikhail Byakhow is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Mikhail Byakhow has authored 2 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Oncology, 2 papers in Cancer Research and 1 paper in Pathology and Forensic Medicine. Recurrent topics in Mikhail Byakhow's work include HER2/EGFR in Cancer Research (2 papers), Breast Cancer Treatment Studies (2 papers) and Monoclonal and Polyclonal Antibodies Research (1 paper). Mikhail Byakhow is often cited by papers focused on HER2/EGFR in Cancer Research (2 papers), Breast Cancer Treatment Studies (2 papers) and Monoclonal and Polyclonal Antibodies Research (1 paper). Mikhail Byakhow collaborates with scholars based in Spain, Switzerland and Italy. Mikhail Byakhow's co-authors include Luca Gianni, José Baselga, Semiglazov Vf, Milvia Zambetti, W. Eiermann, Federico Vázquez, Pinuccia Valagussa, Mauro Mansutti, S. Tjulandin and Eva Ciruelos and has published in prestigious journals such as The Lancet and Clinical Cancer Research.

In The Last Decade

Mikhail Byakhow

2 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

2010 891 citations Luca Gianni, W. Eiermann et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mikhail Byakhow Spain	2	875	624	309	155	125	2	1.0k
Mauro Mansutti Italy	11	1.2k 1.4×	740 1.2×	358 1.2×	312 2.0×	139 1.1×	29	1.4k
Hannah Douthwaite Spain	6	717 0.8×	428 0.7×	262 0.8×	190 1.2×	78 0.6×	8	835
R. Kokko Finland	12	650 0.7×	410 0.7×	247 0.8×	163 1.1×	107 0.9×	22	836
Jean-François Boileau Canada	4	722 0.8×	440 0.7×	322 1.0×	182 1.2×	91 0.7×	5	856
Alessandra Balduzzi Italy	18	710 0.8×	626 1.0×	99 0.3×	169 1.1×	172 1.4×	35	1.0k
Svjetlana Mohrmann Germany	16	588 0.7×	441 0.7×	222 0.7×	236 1.5×	160 1.3×	63	1.1k
C. Hudis United States	13	632 0.7×	204 0.3×	186 0.6×	100 0.6×	64 0.5×	59	801
R. Ghisini Italy	18	1.0k 1.2×	944 1.5×	159 0.5×	239 1.5×	323 2.6×	34	1.4k
I. Craig Henderson United States	7	903 1.0×	520 0.8×	223 0.7×	112 0.7×	174 1.4×	7	1.1k
А. А. Божок Russia	11	1.6k 1.8×	1.3k 2.1×	446 1.4×	315 2.0×	341 2.7×	22	2.0k

Countries citing papers authored by Mikhail Byakhow

Since Specialization

Citations

This map shows the geographic impact of Mikhail Byakhow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikhail Byakhow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikhail Byakhow more than expected).

Fields of papers citing papers by Mikhail Byakhow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mikhail Byakhow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikhail Byakhow. The network helps show where Mikhail Byakhow may publish in the future.

Co-authorship network of co-authors of Mikhail Byakhow

This figure shows the co-authorship network connecting the top 25 collaborators of Mikhail Byakhow. A scholar is included among the top collaborators of Mikhail Byakhow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mikhail Byakhow. Mikhail Byakhow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

2 of 2 papers shown

1.

Prat, Aleix, Giampaolo Bianchini, Marlène Thomas, et al.. (2014). Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study. Clinical Cancer Research. 20(2). 511–521. 158 indexed citations

2.

Gianni, Luca, W. Eiermann, Semiglazov Vf, et al.. (2010). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet. 375(9712). 377–384. 891 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact